Find Clinical Trials

Answer each question to find trials that best match your clinical situation. You can leave questions blank if you do not know the answer.

This search will output a list of trials for which you may be eligible based on the criteria you enter.

Matching Trials

For more detailed information please click on the clinical trial number and you will be taken to the clinicaltrials.gov website.
For a key to the icons and text used in the Results column, please click here.
To learn more about our trial annotation process, results assignments, and the criteria used to highlight drugs with promising results, please click here.

  Clinical Trial Phase Eligible Participant Official Title Location Drugs in Trial Results
NCT03772028IIINewly diagnosed stage III ovarian cancer eligible for primary cytoreductive surgeryPhase III Randomized Clinical Trial for Stage III Epithelial Ovarian Cancer Randomizing Between Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal ChemotherapyCA, NYView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CisplatinCACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, PlatosinDNA damaging agentApproved in Ovarian Cancer
HIPECHyperthermic Intraperitoneal ChemotherapyNCCN Guidelines for Ovarian Cancer
NCT05659381IIINewly diagnosed stage III/IV high grade serous or endometrioid ovarian cancer (neo-adjuvant)GOG-3068: A Phase III Randomized Trial of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) With Cisplatin Versus no HIPEC at the Time of Optimal Interval Cytoreductive Surgery Followed by Niraparib Maintenance in Patients With Newly Diagnosed Stage III and IV Ovarian, Primary Peritoneal, and Fallopian Tube Cancer (Heated Ovarian Treatment Trial)CA, KY, NJ, OH, PAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CarboplatinParaplatin, NovoplatinumDNA damaging agentApproved in Ovarian Cancer
CisplatinCACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, PlatosinDNA damaging agentApproved in Ovarian Cancer
HIPECHyperthermic Intraperitoneal ChemotherapyNCCN Guidelines for Ovarian Cancer
NiraparibMK4827, ZejulaPARP inhibitorApproved in Ovarian Cancer
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitorApproved in Ovarian Cancer
NCT04095364IIINewly diagnosed stage II-IV low grade serous ovarian cancer without mutations in TP53 after debulking surgeryA Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients With Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or PeritoneumAK, AZ, AR, CA, CO, CT, DE, DC, FL, GA, HI, ID, IL, IN, IA, KS, KY, LA, ME, MD, MA, MI, MN, MS, MO, MT, NE, NV, NJ, NM, NY, NC, ND, OH, OK, OR, PA, RI, SC, SD, TN, TX, UT, VA, WA, WV, WI, WYView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CarboplatinParaplatin, NovoplatinumDNA damaging agentApproved in Ovarian Cancer
LetrozoleFemaraAromatase inhibitorNCCN Guidelines for Ovarian Cancer
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitorApproved in Ovarian Cancer
NCT06175221IIaStage I-IV solid tumors (fresh tumor available)A Prospective, Open-Label, All-Comers Phase IIa Trial of The Tumor Lysate, Particle Only (TLPO) Cancer Vaccine in Solid Tumor MalignanciesSCView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
TLPO vaccineImmune response against tumor associated antigensClinical Trials
NCT04606914IINewly diagnosed stage III/IV high grade serous FRalpha high+ ovarian cancer (neo-adjuvant)Single-Arm Phase II Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer Who Are Folate Receptor α PositiveALView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CarboplatinParaplatin, NovoplatinumDNA damaging agentApproved in Ovarian Cancer
Mirvetuximab soravtansineM9346A-sulfo-SPDB-DM4, IMGN853, Anti-FOLR1-mab Maytansinoid ConjugateADC: anti-FRalpha + microtubule destabilizer (DM4)Approved in Ovarian Cancer
NCT06394804IINewly diagnosed low grade serous ovarian cancer that is not a primary surgical candidates or with residual disease after surgeryCombination Targeted and Hormonal treAtMEnt of Low-gradE Serous Ovarian Cancer in the upfroNt SettingNJ, NYView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AvutometinibCH5126766, Raf/MEK dual kinase inhibitor RO5126766, RO5126766, CKI27, VS-6766RAF and MEK inhibitorClinical Trials
DefactinibVS-6063, PF-04554878, PF-04554878FAK inhibitorClinical Trials
LetrozoleFemaraAromatase inhibitorNCCN Guidelines for Ovarian Cancer
NCT03574779IINewly diagnosed stage III/IV ovarian cancer that is HRD+ (neo-adjuvant)A Phase 1B/2 Multicohort Umbrella Study to Evaluate the Safety and Efficacy of Novel Treatments And/Or Combinations of Treatments in Participants With Ovarian Cancer (OPAL)CA, IL, ME, MA, MN, OK, SD, WAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Bevacizumabimmunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, AvastinVEGF antagonistApproved in Ovarian Cancer
CarboplatinParaplatin, NovoplatinumDNA damaging agentApproved in Ovarian Cancer
NiraparibMK4827, ZejulaPARP inhibitorApproved in Ovarian Cancer
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitorApproved in Ovarian Cancer
NCT05145569IINewly diagnosed stage III/IV high grade serous ovarian cancer (neo-adjuvant)A Phase 2 Open-Label Study to Assess the Antitumor Activity of Neoadjuvant Chemotherapy With or Without HCW9218 in Patients With Metastatic Advanced Stage Ovarian CancerPAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CarboplatinParaplatin, NovoplatinumDNA damaging agentApproved in Ovarian Cancer
HCW9218IL-15R agonist and TGFbeta trapClinical Trials
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitorApproved in Ovarian Cancer
NCT05739981I/IINewly diagnosed stage III/IV high grade serous ovarian cancer (neo-adjuvant and maintenance)Phase II Study Evaluating the Effect of IMNN-001 on Second Look Laparoscopy (SLL) in Combination With Bevacizumab (BEV) and Neoadjuvant Chemotherapy (NACT) in Newly Diagnosed With Advanced Ovarian, Fallopian Tube or Primary Peritoneal CancerNY, TXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Bevacizumabimmunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, AvastinVEGF antagonistApproved in Ovarian Cancer
CarboplatinParaplatin, NovoplatinumDNA damaging agentApproved in Ovarian Cancer
IMNN-001IMNN-001, PEG-PEI-cholesterol lipopolymer-encased IL-12 DNA plasmid vector GEN-1, EGEN-001, phIL-12-005/PPC, GEN-1IL-12R agonistClinical Trials
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitorApproved in Ovarian Cancer
NCT05276973I/IbNewly diagnosed stage III/IV high grade serous or high grade endometrioid ovarian cancer (neo-adjuvant)Phase I/IB Safety and Pharmacodynamic Study of Neoadjuvant (NACT) Paclitaxel and Carboplatin With Ipatasertib as Initial Therapy of Ovarian Cancer PTMA 100805CA, GA, OH, OK, PA, RI, VA, WIView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CarboplatinParaplatin, NovoplatinumDNA damaging agentApproved in Ovarian Cancer
IpatasertibGDC-0068, Akt Inhibitor GDC-0068, RG7440pan-AKT inhibitorClinical Trials
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitorApproved in Ovarian Cancer
NCT04847063INewly diagnosed or recurrent ovarian cancer with peritoneal diseaseIndividualized Response Assessment to Heated Intraperitoneal Chemotherapy (HIPEC) for the Treatment of Peritoneal Carcinomatosis From Ovarian, Colorectal, Appendiceal, or Peritoneal Mesothelioma HistologiesMDView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
CisplatinCACP, cis-DDP, cis-platinum, CDDP, Platinol, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, Citosin, Lederplatin, Metaplatin, Neoplatin, Placis, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platiran, Platistin, PlatosinDNA damaging agentApproved in Ovarian Cancer
Doxorubicin14-Hydroxydaunomycin, Hydroxyl-DaunorubicinTopoisomerase II inhibitorApproved in Other Cancers
HIPECHyperthermic Intraperitoneal ChemotherapyNCCN Guidelines for Ovarian Cancer
OxaliplatinOHP, Eloxatine, Dacplat, Dacotin, EloxatinDNA damaging agent
SurgeryClinical Trials
NCT05080946INewly diagnosed high grade ovarian cancer (neo-adjuvant)Pilot Study to Assess the Efficacy of Aspirin to Improve Immunological Features of Ovarian TumorsFL, VAView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Acetylsalicylic acidAspirinCOX-1/2 inhibitorApproved in Other Indications
CarboplatinParaplatin, NovoplatinumDNA damaging agentApproved in Ovarian Cancer
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitorApproved in Ovarian Cancer
Placebo

If you have any questions or would like help with your search, please call us at: 858-264-6889 or email us at patientsupport@clearityfoundation.org.